Dianthus Therapeutics (DNTH) Long-Term Deferred Tax (2017 - 2024)
Dianthus Therapeutics (DNTH) recorded quarterly Long-Term Deferred Tax of $21.7 million in Q4 2024, up 73.6% quarter-over-quarter from $12.5 million in Q4 2017.
Dianthus Therapeutics (DNTH) Long-Term Deferred Tax (2017 - 2024) Analysis & Trends
Dianthus Therapeutics' Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $21.7 million for Q4 2024.
- In Q4 2024, Long-Term Deferred Tax changed N/A year-over-year to $21.7 million; the TTM figure through Dec 2024 stood at $21.7 million (changed N/A YoY), while the FY2024 annual figure was $21.7 million, changed N/A from the prior year.
- Long-Term Deferred Tax was $21.7 million for Q4 2024 at Dianthus Therapeutics, up from $12.5 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $21.7 million in Q4 2024 to a low of $21.7 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Dianthus Therapeutics | 3.60 Bn | 3.19 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 21.70 Mn |
| Dec 31, 2017 | 12.50 Mn |